Discontinuation of Development. In the event Amgen shall at any time elect to discontinue all development and commercialization activities relating to Licensed Products, Amgen will notify Progenitor in writing of such election and upon Progenitor's receipt of such notification, this Agreement will terminate and all licenses under the Licensed Patents granted to Amgen and its Affiliates hereunder will revert to Progenitor.
Discontinuation of Development. If after completion of all Development activities under the applicable Joint Phase IIb Plan, both Parties’ representatives on the applicable JDC agree that the Development of the applicable Product Candidate in such Indication shall be discontinued, then such Product Candidate shall be discontinued as a Product Candidate for such Indication and returned to the JEC for a determination as to whether it should be: (A) re-designated as a Development Candidate for additional Exploratory Development Activities pursuant to Article 4, or (B) retained as a Product Candidate, but for another Indication to be selected by the JEC and then referred again to the JDC under this Article 5.
Discontinuation of Development. Solvay agrees to notify ArQule if it decides to discontinue development or marketing of any Licensed Compound or Derivative Compounds thereof. In addition, throughout the term of this Agreement, Solvay will submit to ArQule annual written reports and semi-annual verbal reports of the activities of Solvay and its Affiliates with respect to all such compounds during the reporting period. These reports will include relevant chemical and biological data and other information sufficient to allow ArQule to determine whether Solvay and/or its Affiliates are engaging in significant activity with respect to each such compound prior to Project Declaration. The information in such reports shall be considered Confidential Information under Section 10.1. hereof. During the Research Period, Solvay shall provide such reports on a schedule such that they can be reviewed at the meetings of the Research Committee. In addition, Solvay agrees to inform ArQule at least once each calendar year regarding the status of any Solvay Derivative Compounds that Solvay develops based on Solvay Derivative Compounds synthesized by ArQule under this Agreement.
Discontinuation of Development. During the term of this Agreement, and for a period of ****** years thereafter, in the event Lilly desires to license or discontinue development of a CART Identified Compound or Drug Product, Lilly hereby grants to Arena a right to negotiate a license to such CART Identified Compound or Drug Product. Lilly shall provide to Arena written Notice of such desire to license or discontinue development of such CART Identified Compound or Drug Product.
Discontinuation of Development. If after completion of all Development activities under the applicable Joint Phase IIb Plan, both Parties’ representatives on the applicable JDC agree that the Development of the applicable Product Candidate in such Indication shall be discontinued, then such Product Candidate shall be discontinued as a Product Candidate for such Indication and returned to the JEC for a determination as to whether it should be: (A) re-designated as a Development Candidate for additional Exploratory Development Activities pursuant to Article 4, or (B) retained as a Product Candidate, but for another Indication to be selected by the JEC and then referred again to the JDC under this Article 5. Specific terms in this exhibit have been redacted because confidential treatment for those terms has been requested. These redacted terms have been marked in this exhibit with three asterisks [***]. An unredacted version of this exhibit has been separately filed with the Securities and Exchange Commission.
Discontinuation of Development. If the Committee decides to discontinue Developing a ThermoDox Product, the Development Plan for such ThermoDox Product shall immediately terminate upon such decision. Upon such determination by the Committee, the Committee shall remove such Named Indication(s) from Schedule 1.53 unless otherwise agreed to by the Parties.
Discontinuation of Development. If SANKYO discontinues development of all Compounds pursuant to the Research Program then SANKYO shall immediately notify OSI thereof and OSI shall have the sole and exclusive right, subject to the payment of royalties as set forth in this Article 2.4.2, to pursue development of any and all Compounds, and to develop, make, have made, use, and sell Products containing any Compound, provided, however, this clause shall not apply to any Compound which SANKYO has included in a sub-license to a third party prior to its decision to discontinue development of all Compounds. No royalties, milestone payments or any other payments shall be payable by OSI to the other parties hereto with respect to such Compounds; provided, however, that (i) OSI shall pay to SANKYO a royalty at the rate of ** of the Net Sales of OSI for each Product derived from such Compound, the manufacture, use or sale of which is covered by a Valid Claim of the Patent Rights, which royalty OSI shall continue to pay in each applicable country until the expiration of the last Valid Claim under the Patent Rights applicable to such Product expires in such ----------------------- ** This portion redacted pursuant to a request for confidential treatment.
Discontinuation of Development. Solvay Duphar agrees to notify ArQule if it decides to discontinue development or marketing of any Active ArQule Compound or Derivatives thereof. In addition, throughout the term of this Agreement, Solvay Duphar will submit to ArQule quarterly reports of the activities of Solvay Duphar and its Affiliates with respect to all such compounds during the prior three-month period. These reports will include relevant chemical and biological data and other information sufficient to allow ArQule to determine whether Solvay Duphar and/or its Affiliates are engaging in significant activity with respect to each such compound prior to Project Declaration. The information in such reports shall be considered Confidential Information under Section 10.1. hereof. During the Research Period, Solvay Duphar shall provide such reports on a schedule such that they can be reviewed at the quarterly meetings of the Research Committee.
Discontinuation of Development. In the event that Celgene fails to develop at least one Licensed Product pursuant to Section 3.1, then Celgene agrees to negotiate in good faith with CMCC to sublicense under commercially reasonable terms a Licensed Product to a third party.
Discontinuation of Development. If the JSC determines to discontinue Developing a Licensed Product upon recommendation by the JDC, the Development Plan for such Licensed Product shall terminate upon such decision. Upon such determination by the JSC, the JSC shall remove such Named Compound or the relevant Named Indication(s) from Schedule 1.65 or 1.66, as applicable, pursuant to Section 4.1.2(e) at its next scheduled meeting (which in any event shall be no later than three (3) months after such determination) unless there is a Development Plan or Commercialization Plan for any Licensed Product with respect to such Named Compound or such Named Indication in effect at such time of such JSC determination or unless otherwise agreed to by the Parties.
